Profile: Agenus Inc (AGEN.O)
9 Dec 2013
Agenus Inc., including its subsidiaries, (Agenus) is a biotechnology company focused on the development and commercialization of technologies to treat cancers and infectious diseases. The Company's core technology portfolio consists of its Saponin Platform (based on its saponin adjuvant based technologies) and its Heat Shock Protein (HSP) Platform (based on its HSP based technologies). The Company's key candidates from these technology platforms include QS-21 Stimulon adjuvant (QS-21), the Prophage Series vaccines and HerpV. The Company's products and technologies under development include QS-21. A number of pharmaceutical and biotechnology companies have licensed QS-21 from the Company for use in vaccines to treat a wide variety of human diseases. The Company has retained worldwide manufacturing rights for QS-21. It has the right to subcontract manufacturing for QS-21 and it has a supply agreement with a contract manufacturer for the production of QS-21 through September 2012. The Prophage Series vaccines describe its portfolio of patient-specific HSP-based therapeutic cancer vaccines, including the R-Series candidates in renal cell carcinoma (RCC), M-Series candidates in melanoma, and G-Series candidates in glioma.
QS-21 Stimulon adjuvant (QS-21)
QS-21, from the Company's Saponin Platform, is an adjuvant, or a substance added to a vaccine or other immunotherapy that is intended to enhance immune response. The key licensees of QS-21 are GlaxoSmithKline (GSK) and JANSSEN Alzheimer Immunotherapy (JANSSEN AI). There are approximately 15 vaccines containing QS-21 in clinical development by the Company's licensees, including a total of four in Phase 3 testing for malaria, melanoma, non-small cell lung cancer and shingles.
The Prophage Series vaccines
The Prophage Series vaccines are a patient specific application of the Company's HSP Platform. The Prophage Series vaccine R-100 is referred to as Oncophage vaccine (vitespen) and is approved in Russia for the treatment of RCC, kidney cancer in patients at intermediate risk of recurrence. In December 2011, the Company secured a local partner for Oncophage when the Company granted NewVac LLC (a subsidiary of ChemRar Ventures LLC, NewVac) an exclusive license to manufacture, market and sell Oncophage. In addition, Phase 2 trials are underway in the United States testing the Prophage Series vaccine candidates G-100 and G-200 in newly diagnosed and recurrent glioma, respectively.
Also derived from the Company's HSP Platform technologies, HerpV is produced therapeutic vaccine candidate for the treatment of genital herpes. It has completed Phase 1 testing. The Company is seeking partners for select products in its portfolio, which include the Prophage G-Series vaccine candidates, G-100 and G-200, QS-21 and HerpV.
QS-21 Stimulon adjuvant, from the Company's Saponin Platform, is an adjuvant, or a substance added to a vaccine or other immunotherapy that is intended to enhance immune response. The key licensees of QS-21 are GSK and JANSSEN AI. There are approximately 15 vaccines containing QS-21 in clinical development, including a total of four in Phase 3 testing for malaria, melanoma, non-small cell lung cancer and shingles. The pipeline of product candidates containing QS-21 is diverse, encompassing prophylactic, as well as therapeutic vaccines for infectious diseases, multiple cancer types, and Alzheimer's disease.
3 Forbes Road
NEW YORK NY 10010